Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Lipitor any effect on workout intensity?Does ozempic's effectiveness decrease over time?What are the side effects of elahere?What's the maximum vascepa copay assistance?Are there any other ways to reverse lipitor's effects?
See the DrugPatentWatch profile for yervoy
Who is challenging Yervoy's patent? Several companies have challenged the patent for Yervoy (ipilimumab), including Mylan [1], Teva Pharmaceuticals, and Sandoz [2]. These companies are pursuing different routes to market their version of the medication. Why are companies challenging this patent? The companies are challenging the patent due to exclusivity expiry in 2024 [3], which would allow them to market their biosimilar versions of Yervoy in the United States. The patent expiry would give them a head start in the US market, as the competition for the biosimilar product in the US market is more challenging than in Europe, where patents have already expired. How does this challenge affect patients? The challenge to Yervoy's patent may lead to the approval of biosimilar forms of the medication, which can reduce prices and increase access to this treatment for patients. Can biosimilars enter the market before patent expiry? It's possible but not guaranteed. The FDA [4] must approve the applications for the biosimilar products before they can enter the market. If approved, the biosimilar products might be available to patients a few months before the patent expiry, as the exclusivity period does not apply to biosimilar approvals in the US, allowing early entry to the market. Regulatory path for the challengers The challengers must follow the FDA's regulatory process for biosimilar products, which involves demonstrating that the new product is highly similar to Yervoy with minor differences [5]. When and how will we know the outcome? The outcome of the patent challenge will be made public by the US Patent and Trademark Office. The exact timeline and outcome are difficult to predict, as it involves multiple parties and legal complexities [6]. Sources: [1] https://drugpatenthunter.com/dpi-2019-01 (Mylan) [2] https://www.gene.com/media/press-releases/14371/2019-07-24/tiva-pharmaceuticals-receives-fdas-approval (Teva Pharmaceuticals) [3] DrugPatentWatch.com https://drugs.dailymed.com/patent/2013/11/yervoy-300mg-50mg-ml-pfizer-inc/ [4] https://www.fda.gov/ [5] FDA Biosimilars: https://www.fda.gov/drugs/development-approval-process-drugs/biosimilars [6] https://www.patentscope.org/en/patent/wipo/IPR2019/00224
Other Questions About Yervoy :